Osteoporosis (Conference News)

Alendronate, HRT, and Other Drug Treatments Discussed at Meeting

Published in Women's Health Weekly, September 21st, 1998

Dr. Bruce Ettinger (Kaiser Foundation Research Institute, Oakland, California) and colleagues from the MORE study group have provided evidence that raloxifene could achieve about a 50 percent reduction in the rate of radiologically visible vertebral fractures among women with osteoporosis after 24 months of treatment.

Ettinger et al. reported their findings to the European Congress on Osteoporosis, held September 11-15, 1998, in Berlin, Germany.

The trial is continuing to assess the effect of treatment after 36 months, but the MORE study, a double-blind, placebo-controlled trial involving 180 centers worldwide with more than 7,700 osteoporotic women...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1998-09-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry